Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Antibiotics

Rutgers Research: Antibiotics from a ‘Molecular Pencil Sharpener’; Discovery Could Lead to New Antibacterial Agents and Drugs

New Brunswick, NJ, October 24, 2017 — Picture a brand-new, unsharpened pencil. The graphite at its core can’t be used for writing until a pencil sharpener chews away its wooden tip.

Now picture microcin B17, an antibiotic that kills E. coli bacteria. Before being activated, it lies embedded in a structure called a prodrug, like the core of an unsharpened “molecular pencil.”

Todd B. Bates reports that now, for the first time, scientists at Rutgers University–New Brunswick and other institutions have discovered a “molecular pencil sharpener” that chews away its outer coating to release the powerful antibiotic. Continue reading

CDC Funds 34 Innovative Projects to Combat Antibiotic Resistance; Research Aims to Better Understand Role of Microbiome

CDC LogoAtlanta, GA, October 8, 2016 — The Centers for Disease Control and Prevention (CDC) has awarded more than $14 million to fund new approaches to combat antibiotic resistance, including research on how microorganisms naturally present in the human body (referred to as a person’s microbiome) can be used to predict and prevent infections caused by drug-resistant organisms.

The awards, made through CDC’s Broad Agency Announcement (BAA), support activities in the CDC Antibiotic Resistance Solutions Initiative.

The initiative, which also provides funding for state health departments and other partners, implements the tracking, prevention, and antibiotic stewardship activities outlined in the National Action Plan for Combating Antibiotic-Resistant Bacteria. Continue reading

Growing Antibiotic Resistance Forces WHO to Update Recommended Treatment for Sexually Transmitted Diseases

WHOGeneva, Switzerland, August 31, 2016 — New guidelines for the treatment of three common sexually transmitted infections (STIs) have been issued by the World Health Organization (WHO) in response to the growing threat of antibiotic resistance.

Chlamydia, gonorrhea and syphilis are all caused by bacteria and are generally curable with antibiotics. However, these STIs often go undiagnosed and are becoming more difficult to treat, with some antibiotics now failing as a result of misuse and overuse.

It is estimated that, each year, 131 million people are infected with chlamydia, 78 million with gonorrhea, and 5.6 million with syphilis. Continue reading

U.S. Patient’s Infection Raises Specter of Superbugs Resistant to All Antibiotics

Superbug definitionNew York, NY, May 31, 2016 ― Sabrina Tavernise and Denise Grady reported in The New York Times that American military researchers have identified the first patient in the United States to be infected with bacteria that are resistant to an antibiotic that was the last resort against drug-resistant germs.

The patient is well now, but the case raises the specter of superbugs that could cause untreatable infections, because the bacteria can easily transmit their resistance to other germs that are already resistant to additional antibiotics.

The resistance can spread because it arises from loose genetic material that bacteria typically share with one another. Continue reading